Review
Nature Reviews Cancer 6, 688-701 (September 2006) | doi:10.1038/nrc1958
Polymer conjugates as anticancer nanomedicines
Ruth Duncan1 About the author
Top of page
Abstract
The transfer of polymer–protein conjugates into routine clinical use, and the clinical development of polymer–anticancer-drug conjugates, both as single agents and as components of combination therapy, is establishing polymer therapeutics as one of the first classes of anticancer nanomedicines. There is growing optimism that ever more sophisticated polymer-based vectors will be a signficant addition to the armoury currently used for cancer therapy.
- View At a Glance
Author affiliations
- Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK. Email: Duncanr@cf.ac.uk
Published online 10 August 2006
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470Nature Medicine Article (01 Mar 2004)
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapyBritish Journal of Cancer Original Article
See all 4 matches for Research